Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey

  • Sizulu Moyo ,

    Roles Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing,

    Affiliations Human Sciences Research Council, Pretoria, South Africa, School of Public Health, University of Cape Town, Cape Town, South Africa

  • Gillian Hunt,

    Roles Conceptualization, Investigation, Methodology, Resources, Writing – review & editing

    Affiliation Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa

  • Khangelani Zuma,

    Roles Formal analysis, Methodology, Project administration, Resources, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Mpumi Zungu,

    Roles Project administration, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Edmore Marinda,

    Roles Writing – review & editing

    Affiliations Human Sciences Research Council, Pretoria, South Africa, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa

  • Musawenkosi Mabaso,

    Roles Formal analysis, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Vibha Kana,

    Roles Investigation

    Affiliation Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa

  • Monalisa Kalimashe,

    Roles Investigation

    Affiliation Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa

  • Johanna Ledwaba,

    Roles Investigation

    Affiliation Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa

  • Inbarani Naidoo,

    Roles Formal analysis, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Sinovuyo Takatshana,

    Roles Formal analysis, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Tebogo Matjokotja,

    Roles Formal analysis, Writing – review & editing

    Affiliation Human Sciences Research Council, Pretoria, South Africa

  • Cheryl Dietrich,

    Roles Project administration, Writing – review & editing

    Affiliation Division of Global HIV and TB, Centers for Disease Control and Prevention, Pretoria, South Africa

  • Elliot Raizes,

    Roles Writing – review & editing

    Affiliation Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, GA, United States of America

  • Karidia Diallo,

    Roles Project administration, Writing – review & editing

    Affiliation Division of Global HIV and TB, Centers for Disease Control and Prevention, Pretoria, South Africa

  • Gurpreet Kindra,

    Roles Writing – review & editing

    Affiliation Division of Global HIV and TB, Centers for Disease Control and Prevention, Pretoria, South Africa

  • Linnetie Mugore,

    Roles Writing – review & editing

    Affiliation Division of Global HIV and TB, Centers for Disease Control and Prevention, Pretoria, South Africa

  •  [ ... ],
  • Thomas Rehle

    Roles Conceptualization, Formal analysis, Funding acquisition, Writing – review & editing

    Affiliation School of Public Health, University of Cape Town, Cape Town, South Africa

  • [ view all ]
  • [ view less ]



HIV drug resistance (HIVDR) testing was included in the 2017 South African national HIV household survey. We describe the prevalence of HIVDR by drug class, age, sex and antiretroviral drugs (ARV) status.


Dried blood were spots tested for HIV, with Viral load (VL), exposure to ARVs and HIVDR testing among those HIV positive. HIVDR testing was conducted on samples with VL ≥1000 copies/ml using Next Generation Sequencing. Weighted percentages of HIVDR are reported.


697/1,105 (63%) of HIV positive samples were sequenced. HIVDR was detected in samples from 200 respondents (27.4% (95% confidence interval (CI) 22.8–32.6)). Among these 130 (18.9% (95% CI 14.8–23.8)), had resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) only, 63 (7.8% (95% CI 5.6–10.9)) resistance to NNRTIs and nucleoside reverse transcriptase inhibitors, and 3 (0.5% (95% CI 0.1–2.1)) resistance to protease inhibitors. Sixty-five (55.7% (95% CI 42.6–67.9) of ARV-positive samples had HIVDR compared to 112 (22.8% (95% CI 17.7–28.7)), in ARV-negative samples. HIVDR was found in 75.6% (95% CI 59.2–87.3), n = 27, samples from respondents who reported ARV use but tested ARV-negative, and in 15.3% (95% CI 6.3–32.8), n = 7, respondents who reported no ARV use and tested ARV-negative. There were no significant age and sex differences in HIVDR.


27% of virally unsuppressed respondents had HIVDR, increasing to 75% among those who had discontinued ARV. Our findings support strengthening first-line ARV regimens by including drugs with a higher resistance barrier and treatment adherence strategies, and close monitoring of HIVDR.


Access to antiretroviral therapy (ART) has expanded globally in the last decade, reaching 25.4 million individuals in 2017 [1]. Of the 20.7 million people living with HIV (PLHIV) in Eastern and Southern Africa in 2017, 15 million were on treatment [1]. In South Africa, more than 7 million people were living with HIV in 2017, and 4.4 million of them were receiving ART [2]. The country plans to further expand treatment coverage in line with the National Strategic Plan for HIV, Tuberculosis) (TB) and sexually transmitted infections (STIs) 2017–2022 (NSP 2017–2022) [3], which aims to achieve the 90–90–90 Joint United Nations Programme on HIV/AIDS targets [4] in every district by 2022.

Universal test and treat and reduced mortality in PLHIV [5] have meant more individuals on ART for longer periods of time, and consequently, the emergence of HIV drug resistance (HIVDR) [6]. Weaknesses in HIV treatment programmes, including high default rates, poor viral suppression levels, limited viral load (VL) testing, delayed response to high VL, and limited testing for resistance, can further increase the levels of HIVDR. HIVDR can undermine the benefits and successes of ART programmes [6, 7] and jeopardize the achievement of the 90–90–90 treatment targets, specifically VL suppression which has a direct impact on new infections [4]. The World Health Organization (WHO) therefore recommends surveillance for HIVDR through routine monitoring for early indicators of poor HIV programme performance, surveillance for pre-treatment resistance (PDR), and evaluation of resistance acquired during therapy failure [6].

Data indicates increasing levels of HIVDR across the world. A systematic review of 26 studies in low- and middle-income countries (LMIC) conducted between 2014 and 2017, found that 9.7% of adults on ART had HIVDR [7], and most prevalent amongst those on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in Southern and Western African countries (>87%). Prevalence of pretreatment NNRTI resistance in in southern Africa in 2016 was estimated at 11% with a yearly increase in odds of 23% [7]. Within Southern and Central Africa, recent studies have reported PDR rates ranging from 9% to 16.3% [811]. A provincial surveillance system in South Africa found PDR prevalence of 11% over the period 2014–2015 [12], while sentinel surveillance estimated national TDR prevalence (NNRTI) at 5.4% [13]. In Population HIV Impact Assessment surveys (PHIAs) conducted in Malawi and Zimbabwe (respondents 15–59 years), Drug Resistant Mutations (DRMs) were detected in 4/26 (15%) and 3/30 (10%) of individuals classified as recently infected with HIV, respectively, consistent with the prevalence observed in the PDR surveys in the African Region [6].

This study presents the profile of HIVDR among PLHIV enrolled and tested in a nationally representative HIV household survey conducted in South Africa in 2017 [2].


Design and sampling

The national HIV household survey was a national cross-sectional survey that included people of all ages in all provinces of South Africa, in 2017. The survey included people living in hostels while those living in educational institutions, old-age homes, hospitals, and uniformed-service barracks were excluded. All members of the selected households were invited to participate. The design was similar to that implemented in four previous HIV surveys conducted in 2002, 2005, 2008, and 2012 [1417], as was targeted to be representative of the general population in the country. A stratified master sample of 1000 small area layers (SALs) was randomly sampled with probability proportional to size. The sample was stratified by province and locality type [urban, rural formal (farms) and rural informal (traditional rural villages)], as defined by Statistics South Africa [18]. A systematic random sample of 15 households was selected within each sampled SAL. Data collection took place between December 2016 and January 2018, and sample analysis was completed in June 2018.

Data collection, and biomarker testing

Survey interviews and collection of blood samples were undertaken in the household after written or verbal consent (for minors, guardian consent with assent as appropriate). Effort was made to ensure confidentiality of the interview process, data transmission and processing. The questionnaires included a household questionnaire for household information and age targeted questionnaires, one for parents/guardians of children aged 0 to 11 years, one for adolescents aged 12 to 14 years, and one for those aged 15 years and older. The questionnaires included a question about daily use of ARVs.

Dried blood spot (DBS) samples were collected by finger prick (or heel prick in infants) and were tested for HIV antibodies using an algorithm with two different enzyme immunoassays (EIAs) and a nucleic acid amplification test (NAAT) for validating all positives. The HIV status of children under two years old was confirmed with the NAAT. Testing for HIV antibodies was conducted at Global Clinical and Viral laboratories in Durban South Africa, with quality assurance testing conducted at the South African Medical Council. HIV-positive (HIV+ve) specimens were further tested for: i) antiretroviral drugs (ARVs), ii) HIV VL, iii) Limiting Antigen (LAg) Avidity EIA (LAg-Avidity EIA, Portland, USA) as part of a multisassay incidence estimation algorithm that took into account ARV treatment and HIV VL [2], in samples from respondents 2 years and older, and iv) HIVDR genotyping for HIVDR.

Testing for ARVs was by High Performance Liquid Chromatography coupled with Tandem Mass Spectrometry [17], and included ARVs in first-, second-, and third-line ART in the public sector in South Africa at the time: nevirapine, efavirenz, atazanavir, darunavir, and lopinavir. The limit of detection was set at 0.02 μg/ml for each drug with a signal-to-noise ratio of at least 5:1 for all the drugs. Samples testing positive for at least one drug were classified as ARV positive (ARV+ve) and those testing negative for all drugs were classified as ARV negative (ARV-ve). Participants who reported that they were taking ARVs daily but tested negative for ARVs in the laboratory were classified as ARV defaulters. Those who reported not taking ARVs regularly and tested negative for ARVs in the laboratory we classified as potentially ARV naïve. (We had no further data to confirm this). Testing for ARVs was undertaken at the Division of Clinical Pharmacology in the Department of Medicine at the University of Cape Town, South Africa. At the time of our survey most patients on ARVs were on fixed-dose combination therapy such as TDF/FTC/EFV (TEE) or TDF/3TC/EFV (TLE). By selecting Efavirenz as the NNRTI ‘backbone’ drug of these combinations we did not need to test for the other NRTI companion drugs, Tenofovir, Emtricitabine or Lamivudine respectively.

VL testing used the Abbott platform (Abbott m2000 HIV Real-Time System, Abbott Molecular Inc., Des Plaines, IL, USA), and was undertaken at the National Institute for Communicable Diseases (NICD) in Johannesburg South Africa. Samples with VL ≥ 1000 copies/ml were classified as virally unsuppressed and were submitted for HIVDR testing.

HIVDR testing was undertaken at the NICD and was conducted by Next Generation Sequencing (NGS). DBS were excised, immersed in 2 ml of NucliSENS lysis buffer (BioMerieux, Nürtingen, Germany) and lysed on a roller mixer at room temperature. Total nucleic acid was extracted using the NucliSENS EasyMAG® automated system according to the manufacturer’s instructions. Amplification of a 1,084 base pair polymerase chain reaction (PCR) fragment consisting of codons 1–99 of protease and codons 1–250 of reverse transcriptase was performed as previously described [19], with the exception of 400 μM of each primer that was used for reverse transcription (RT) polymerase chain reaction (PCR). PCR products were sequenced on the Illumina MiSeq using MiSeq Reagent Kit v3 (Illumina Inc San Diego, CA, USA). FastQ files generated by the Illumina MiSeq were analysed for mutations associated with resistance to ART using Geneious vR9, based on the Stanford v8.0 algorithm and using a 10% prevalence detection threshold. All specimens with a sequence similarity of <1.0% were repeated from extraction for confirmatory purposes [20]. HIVDR mutations were graded using the 3-level grading approach of susceptible, intermediate and high-level resistance using the 2017 update of the Drug Resistance Mutations in HIV-1 list as the reference [21].

Data analysis

Data from samples tested for HIVDR are presented. Survey weights were applied to generate nationally representative estimates, and the analyses took into account the multi-level stratified design of the survey. The final individual weights were benchmarked against the 2017 mid-year population estimates by age, race, age, and province [2]. Weighted data were analysed using STATA version 15 (Stata Corporation, College Station, TX, USA). Estimates are presented as weighted percentages with 95% confidence interval (CI). The Pearson’s Chi Square test was used to compare categorical variables, with p < 0.05 used to determine statistical significance. The median and interquartile range were used to describe continuous variables.


The survey was approved by the Human Sciences Research Council (HSRC) Research Ethics Committee (REC: 4/18/11/15). The study was also reviewed in accordance with the Centers for Disease Control and Prevention (CDC) human research protection procedures and was determined to be research. CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes (CGH 2016-143a).


Samples from 23,836 participants were tested for HIV and among these 2,994 (median age 36 years (interquartile range (IQR) 26–48) tested HIV+ve translating to an estimated HIV prevalence of 14.0% (95% CI 13.1–15.0) [2]. The testing response rate for the entire survey was 61.8% [2]. The survey data were representative of the HIV population in South Africa, with women more likely to provide a blood sample for testing that males [2].

Among the HIV+ve samples with VL results (n = 2,955), 1,105 (37.4%) were virally unsuppressed and among these, 697 (63.1%) were successfully genotyped (see Fig 1), median age 34 years (IQR 27–44). Among those who were virally unsuppressed ARV laboratory data was available for 971 among whom 743 (76.5%) tested ARV negative, and among these 62(8.3%) respondents had reported that they taking ARVs and were defined as ARV defaulters.

Fig 1. Samples tested for HIV drug resistance, South Africa, 2017.

DRT- Drug Resistant Testing; DRMs- Drug Resistant Mutations.

Table 1 shows the characteristics of respondents who provided samples that were successfully genotyped and those that were not. There was no difference in the two groups by sex and locality type. There were significant differences by age and ARV status with a greater proportion of samples from children age 0–14 years among those that were not successfully genotyped, and a greater proportion of samples that tested ART negative that were successfully genotyped.

Table 1. Characteristics of respondents with samples that were successfully genotyped and those that were not.

Overall HIV drug resistance

Resistance was identified in 200/697 samples, giving a prevalence of 27.4% (95% CI 22.8––32.6). Median VL in these samples was 18,913 (IQR 6,150–73,221). The most frequent mutation by drug class was resistance to NNRTIs only, found in 18.9% (95% CI 14.8–23.8), n = 130 of samples (Fig 2). Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was in 0.2% (95% CI 0.1–0.6), n = 4 samples. Dual resistance to NNRTIs and NRTIs was in 7.8% (95% CI 5.6–10.9), n = 63 samples, while resistance to three drug classes NNRTIs, NRTIs, and protease inhibitors (PI) was found in 0.5% (95% CI 0.1–2.1), n = 3 samples.

Fig 2. HIV drug resistance among virally unsuppressed survey respondents, South Africa, 2017.

NNRTI- non-nucleoside reverse transcriptase inhibitors; NRTI- nucleoside reverse transcriptase inhibitors; PI-Protease inhibitors. Bars represent the 95% Confidence interval.

HIV drug resistance by demographic characteristics

Overall, resistance was detected in 29.4% of samples from males and in 25.8% of samples from females, p = 0.473 (Table 2). There was no significant difference between NNRTI-only and dual NNRTI and NRTI resistant samples by sex overall. A third (33.7%) of samples from respondents younger than 14 years had resistance, compared to 30.5% in samples for the youth (15–24 years) and 26.6% from those 25 years and older, p = 0.684. There were no differences in the proportion of respondents with resistance by sex in the different age categories: children younger than 14 years (p = 0.823), youth aged 15–24 years (p = 0.067), those in the reproductive age group (15–49 years) (p = 0.676), and those 50 years and older (p = 0.191). There were also no differences by drug class in these age and sex strata (Table 2).

Table 2. HIV drug resistance by sex, age, and locality type, South Africa, 2017.

Resistance was detected in 29.5% of samples from respondents in urban areas, and in 23.1%, p = 0.077 of samples from rural areas, Table 2. There were no statistically significant differences in the proportion of samples with resistance by drug class between the locality types.

HIV drug resistance by ARV status

Of the 200 samples with HIVDR, 177 had laboratory results for exposure to ARVs, with (65) 29.4% ARV+ve. HIVDR was found in 55.7% of the ARV+ve samples compared to 22.8% in ARV-ve samples p <0.001 (Table 3). When stratified by drug class, 14.3% (95% CI 7.5–25.6) of those who tested ARV+ve had resistance to NNRTIs only compared to 20.0% (95% CI 15.4–25.7) of those who tested ARV-ve, p = 0.311. Dual NNRTI and NRTI resistance was found in 40.4% (95% CI 29.6–52.2) of those who were ARV+ve and in 2.1% (95% CI 0.6–6.8) of those ARV-ve, p<0.001.

Table 3. HIV drug resistance by ARV status, South Africa, 2017.

HIVDR by reported ARV use

Ninety-four samples tested for HIVDR were from respondents who reported daily ARV use at the time of the survey (median age 33 years, IQR 31–45, 53.1% females). Those who reported taking ARVs, but tested ARV-ve were classified as ART defaulters, (n = 41, median age 33 years, IQR 28–38, 56.5% females). HIVDR was detected in 75.9% of these samples, (Table 3); 56.4% of the samples had NNRTI-only resistance (95% CI 34.4–76.2) and 14.3% (95% CI 2.5–52.1) had dual NNRT and NRTI resistance. The sample was too small to estimate resistance to PI-containing regimens.

Thirty-three samples tested for HIVDR were from respondents who reported they were not taking ARVs and tested ARV-ve in the laboratory (median age 38 years, IQR 28–47, and 72.9% were female). HIVDR was detected in 15.3% (95% CI 6.3–32.8) of these samples and all had NNRTI-only resistance. The proportion of HIVDR in this group was significantly lower than in respondents who were taking ARVs, 15.3% vs 55.7% p = 0.004.

HIV drug resistance among respondents recently infected with HIV

HIVDR was detected in 7of 32 samples (21.8% unweighted percentage) recently infected with HIV, and with genotype data available. All seven samples had resistance to NNRTIs (Table 4) and were not on ARVs as our incidence algorithm excluded those on ART [2].

Table 4. HIV drug resistance among respondents classified as recently infected with HIV, South Africa, 2017.


With the largest public sector ART programme in the world, monitoring of population level HIVDR is critical in South Africa since HIVDR levels can impact achievement of the UNAIDS 90–90–90 targets [22]. The HIVDR estimates from this nationally representative HIV survey that were determined by NGS provide useful HIVDR data for all PLHIV in the country. The sample includes virally unsuppressed individuals who may have not yet accessed care, those who may have been disengaged from care (treatment interrupters and defaulters from ART), and those who may have been accessing care from the private sector in addition to those within the public sector ART programme. The data thus represent a comprehensive picture of HIVDR among PLHIV in South Africa.

HIVDR levels were high. Resistance was detected in more than a quarter (27.4%) of samples from virally unsuppressed respondents. Nearly a fifth of the respondents had resistance to NNRTIs. This is consistent with the lower genetic barrier of NNRTIs to resistance [23]. The high HIVDR levels are significant since HIVDR is associated with increased mortality [24, 25] and lower effectiveness of treatment regimens [6], and could severely impact attainment of viral suppression levels needed to end the HIV epidemic [4]. Furthermore, high levels of HIVDR among those on ART (55.7%) highlights a risk of transmission of resistant HIV especially given that in this survey only 28.1% of respondents reported consistent use of condoms [2].

We found low levels of resistance to second-line therapy which includes PIs, and this could indicate appropriate limited prescription of second-line therapy, since PI mutations are much less common than NNRTI and NRTI mutations because PIs have a much higher genetic barrier to resistance [26]. However, limited use of second-line could also be due to other reasons, including lower than ideal levels of VL testing [27] (since levels of VL are key in informing decisions to switch to second-line therapy), poor tolerability, higher cost, and concerns about more frequent dosing in second-line regimens [28]. Analysis of laboratory VL tests undertaken in South Africa between April 2014 and March 2015 showed that 25% of ART clients who were eligible for a VL test during that period had not been tested [27]. In addition, while 78% of ART clients were virally suppressed, only 58% were known to be suppressed by healthcare workers indicating that VL results were not always used to monitor the response to ART [27].

We found NNRTI-monoresistance in samples from 18.9% respondents, and this was the most frequent resistance type as expected in settings where NNRTIs are a key part of first-line treatment regimens. NNRTI mono-resistance also occurred in 15.3% of samples from respondents who tested ARV–ve and reported not taking ARVs. These findings further indicate the low resistance barrier of efavirenz, the most widely used NNRTI in South Africa. Mbuagbaw et al [29] showed that people with pretreatment NNRTI resistance who then receive NNRTI regimens were significantly more likely to experience viral failure or death and were also more likely to discontinue treatment. These findings indicate the importance of regimens that do not contain NNRTIs [6, 30, 31].

HIVDR were most prevalent in samples from respondents with prior exposure to ART (those who reported taking ARVs but tested ARV-ve in the laboratory and were classified as ART defaulters):– 75.9% had DRMs, 56.4% of them with NNRTI mono-resistance. This estimate is much higher than previously reported in South Africa, where HIVDR was found in 37.5% of samples of patients with prior exposure to ART who were enrolled as part of sentinel surveillance in public clinics in three provinces [32]. This difference (75.9% vs 37.5%) could be due to the different populations in these two analyses: household survey vs facility recruitment, or the relatively small sample size in the survey. NNRTI resistance was found in 18.6% of samples in sentinel surveillance compared to 56.4% in the survey, in individuals with prior exposure to ART. Other PDR surveys conducted between 2014 and 2016 in Africa also found that PDR was driven by NNRTI resistance with NNRTI PDR estimates of 17.5% (95% CI 2.3–65.2) and 34.8% (95% CI 25.2–45.8) in Uganda and Namibia, respectively [6].

Our findings of high HIVDR levels among people with prior ART exposure compared to those who reported not taking ARVs and tested ARV-ve are consistent with previous reports that PDR is more than two-fold higher among people starting first-line ART with prior ARV drug exposure, compared to ARV drug-naive individuals [6, 33]. The findings also highlight the impact of poor retention of people in ART care, and the impact on resistance to treatment.

Our estimated HIVDR of 55.7% among virally unsuppressed people on ART is lower than reported from facility-based studies in South Africa. Hunt et al, 2017 [34] found DRMs in 84% and 89% of HIV+ve virally unsuppressed samples from people who had been on ARVs for 12–15 months and 24–36 months respectively in KwaZulu-Natal (KZN), South Africa. Other studies conducted between 2006 and 2012, also in KZN, have reported DRM levels ranging from 83.5% to >97% among people failing therapy [3537]. These discrepancies could be due to the different populations analysed, as facility-based studies more likely to sample PLHIV with clinical symptoms that may correlate with failing therapy and declining CD4 counts, while the survey samples those with more varied adherence and clinical engagement patterns.

Although the numbers are small our finding of 7 samples with DRMs out of 32 samples from respondents recently infected with HIV (21.8%) could suggest higher levels of transmitted HIVDR than found in studies in KZN [3840]. It is also higher than findings from PHIAs conducted, where there were 4/26-15.4% (Malawi) and 3/30-10.0% (Zambia) samples with DRMs from infected samples among adults aged 15–59 years [6].

Rates of successful PCR amplification from dried blood spots were lower than expected. The WHO recommends that DBS specimens with a viral load of >1,000copies/ml be used for HIVDR testing, but acknowledges poor amplification rates at lower VL levels. As we tested all specimens with VL>1,000 copies/ml, this could have contributed to lower overall PCR non-amplification rates [41]. In addition, specimens are maintained at ambient temperature for >2 weeks have increased levels of PCR non-amplification. As we were using two DBS cards for all tests in for this survey, the cards were used for a series other laboratory tests before one became available for HIVDR testing. These successive periods at ambient temperature coupled with freeze-thaw cycles could have contributed to overall specimen degradation [42]

This is the first analysis of HIVDR in a nationally-representative sample of PLHIV in South Africa, and therefore includes PLHIV who are not in care, and those accessing care from the private sector who would be excluded from HIVDR surveillance that utilizes data from public health facilities as recommended by WHO [43]. However, there were some limitations. About a third of virally unsuppressed samples could not be successfully genotyped. Some population sub-groups (e.g. prior ART exposure) are not entirely comparable to those described in the WHO HIVDR reports given the survey approach to data collection. Finally, the sample of incident cases was small, although it was comparable to samples in PHIA surveys conducted in Malawi and Zambia.


Analysis of a nationally representative sample of PLHIV in South Africa, found high levels of resistance to first-line ART regimens among virally unsuppressed PLHIV. HIVDR among people who have defaulted from ART are particularly high. Our findings support strengthening first-line ARV regimens by including drugs with a higher resistance barrier, and treatment adherence strategies, and close monitoring of HIVDR.


We acknowledge all the stakeholders across the country and field staff who contributed to the success of this survey. We also acknowledge and thank all the individuals who participated in the survey.

CDC authorship disclaimer: The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the funding agencies.


  1. 1. UNAIDS, 2019 Global HIV statistics.
  2. 2. Simbayi LC, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. (2018) South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017. Cape Town: HSRC Press
  3. 3. SANAC (South African National Aids Council) (2017). Let Our Actions Count. South Africa’s National Plan on HIV, TB & AIDS and STIs 2017–2022 Pretoria: Department of Health.
  4. 4. UNAIDS (Joint United Nations Programme on HIV/AIDS) (2014a) 90–90–90 An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS
  5. 5. UNAIDS—Global HIV & AIDS statistics—2018 fact sheet.
  6. 6. World Health Organization, 2017. HIV drug resistance report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
  7. 7. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis [published correction appears in Lancet Infect Dis. 2017 Dec 15;]. Lancet Infect Dis. 2018;18(3):346–355. pmid:29198909
  8. 8. Rowley CF, MacLeod IJ, Maruapula D, Lekoko B, Gaseitsiwe S, Mine M et al. Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. J Antimicrob Chemother. 2016; 71(5):1361–6. pmid:26929269
  9. 9. Afonso JM, Bello G, Guimarães ML, Sojka M, Morgado MG. HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola. PLoS ONE. 2012;7(8): e42996. pmid:22952625
  10. 10. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011;11:750–759. pmid:21802367
  11. 11. Steegen K, Carmona S, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, et al. (2016) Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS ONE 11(12): e0166305. pmid:27907009
  12. 12. Chimukangara B, Kharsany ABM, Lessells RJ, et al. Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retroviruses. 2019;35(2):129–138. pmid:30430843
  13. 13. Hunt GM, Ledwaba J, Kalimashe M, et al. Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019;24(3):203–210. pmid:30741163
  14. 14. Shisana O. and Simbayi L. (2002). Nelson Mandela/HSRC Survey of HIV/AIDS: South African national HIV prevalence, behavioural risks and mass media household survey 2002. Cape Town: HSRC Press
  15. 15. Shisana O., Rehle T., Simbayi L., Parker W. Zuma K. et al., (2005). South African national HIV prevalence, incidence, behaviour and communication survey, 2005. Cape Town: HSRC Press. pmid:17600972
  16. 16. Shisana O., Rehle T., Simbayi LC., Zuma K., Jooste S. et al. (2009).South African national HIV prevalence, incidence and communication survey, 2008: A turning tide among teenagers? Cape Town: HSRC Press.
  17. 17. Shisana O., Rehle T., Simbayi LC., Zuma K., Jooste S. et al. (2014). South African National HIV Prevalence, Incidence and Behaviour Survey, 2012. Cape Town, HSRC Press
  18. 18. Stats SA (Statistics South Africa) (2011) Spatial Metadata. Pretoria: Stats SA
  19. 19. Zhou Zhiyong, et al. "Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings." PLoS one 6.11 (2011): e28184. pmid:22132237
  20. 20. Liu TF. & Shafer RW. (2006). Web Resources for HIV type 1 Genotypic-Resistance Test Interpretation. Clin Infect Dis, 42(11):1608–18 pmid:16652319
  21. 21. Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the Drug Resistance Mutations in HIV-1. Top Antivir Med. 2016;24(4):132–133. pmid:28208121
  22. 22. World Health Organization, 2019. HIV drug resistance report 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
  23. 23. Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: Week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70:515–519. pmid:26262777
  24. 24. Pinoges L, Schramm B, Poulet E, Balkan S, Szumillin E, Ferreyra C et al. Risk factors and mortality associated with resistance to first–line antiretroviral therapy: a multicentric cross-sectional and longitudinal analyses. J Acquir Immune Defic Syndr. 2015; 15;68(5) 52735. pmid:25585301
  25. 25. Cambiano V, Bertagnolio S, Jordan MR, Lundgren JD, Phillips A. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis. 2013; 15;207 Suppl pmid:23687290
  26. 26. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med 2012; 18:1378–85, pmid:22941277
  27. 27. Carmona Maya, SI. Better monitoring HIV treatment adherence in South Africa: Using existing data in new ways. NHLS, NDOH:
  28. 28. Meintjes G, Moorhouse MA, Carmona S, et al. Adult antiretroviral therapy guidelines 2017. S Afr J HIV Med. 2017;18(1), a776. pmid:29568644
  29. 29. Mbugbaw L, Aves T, Borhan S, Leenus A, Jordan MJ, Parkin N et al. Systematic reviews and meta-analyses used to inform the guidelines on the public health response to pre-treatment HIV drug resistance. 2017
  30. 30. Guidelines on the public health response to pretreatment HIV drug resistance, July 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
  31. 31. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach –2nd Ed
  32. 32. Puren A, Prospective sentinel surveillance of human immunodeficiency virus related drug resistance NICD communicable diseases communiqué March 2016vol25(3)
  33. 33. Gupta R, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J et al. Global trends in antiretroviral resistance in treatment-naïve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and metaregression analysis. Lancet. 2012; 380:1250–58. pmid:22828485
  34. 34. Hunt G.M. E, Dokubo K, Takuva S, de Oliviera T, Ledwaba J1, Dube N, et al. (2017), Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. Antimicrob Chemotherapy; 72: 3141–8.
  35. 35. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46: 1589–1597. pmid:18419495
  36. 36. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. AIDS 24: 1007–1012. pmid:20397305
  37. 37. Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, et al. (2011) Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr 58: 233–240. pmid:21709569
  38. 38. Manasa K, Katzenstein D, Cassol S, Newell M, de Oliveira T. Primary drug resistance in South Africa- data from 10 years of surveys. AIDS Res Hum Retroviruses. 2012;28:558–65. pmid:22251009
  39. 39. Parboosing R, Naidoo A, Gordon M et al. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 2011; 83: 1508–13. 9 pmid:21739439
  40. 40. Parry CM, Parkin N, Diallo K, et al. Field study of dried blood spot specimens for HIV-1 drug resistance genotyping. J Clin Microbiol. 2014;52(8):2868–2875. pmid:24871219
  41. 41. Parkin N, de Mendoza C, Schuurman R et al. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization Laboratory Network. Clin Infect Dis 2012; 54 Suppl 4(Suppl 4):S273–9 pmid:22544187
  42. 42. Hunt GM, Ledwaba J, Basson AE et al. Surveillance of transmitted HIV-1 drug resistance in the Gauteng and KwaZulu Natal regions of South Africa from 2005–2009. Clin Infect Dis 2012; 54 Suppl 4: S334–8.
  43. 43. World Health Organization, 2014. Surveillance of HIV drugs resistance among adults receiving ART (acquired drug resistance). Geneva, World Health Organization, 2014